Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Pfizer Pledges To Double US Vaccine Output

Plus: Novavax Signs Pact For Equitable Vaccine Access

Executive Summary

A round-up of the latest developments, including Celltrion’s new antibody cocktail and SK Biosience and Novavax expanding their collaboration.

You may also be interested in...



Coronavirus Notebook: Africa Backs IP Waiver Proposal, CEOs To Face EU Parliamentary Hearing On Vaccine Supply

Sanofi and GSK have restarted their Phase II vaccine study, Australia is allowing public advertising of coronavirus vaccines, and Sputnik V has landed in Mexico.

Coronavirus Notebook: UK Pledges To Donate Surplus Vaccines, UN Chief Wants Global Vaccination Plan

Janssen-Cilag has asked for a WHO Emergency Use Listing for its vaccine candidate, while azelastine and carrageenan are both showing promise as potential treatments for COVID-19.

Pfizer And Moderna Reap Rewards Of Expanded US And EU Deals

The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel